INTRA-CELLULAR THERAPIES, INC.

Lobbying for INTRA-CELLULAR THERAPIES, INC. · Biopharmaceutical company

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · New York · House · Senate · $10,000.00 expenses · posted Jul 21, 2025

Bills named in this filing 1

HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…

Lobbying activity 1

Medicare/Medicaid

H.R. 1492 - EPIC Act: Provisions regarding harmonizing small and large molecule period in the Inflation Reduction Act.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.